ASCO® GU 2024 Summary: "Tailoring Prostate Cancer Care - EMBARK Findings, QoL and Real-World Treatment Patterns for High-Risk Biochemically Recurrent Prostate Cancer & Real World Impact of Doublet Therapy in mCSPC"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ASCO® GU 2024 Summary: "Tailoring Prostate Cancer Care - EMBARK Findings, QoL and Real-World Treatment Patterns for High-Risk Biochemically Recurrent Prostate Cancer & Real World Impact of Doublet Therapy in mCSPC"

By Insights from 2024 ASCO® GU Annual Meeting FEATURING Stephen Freedland

0 views

February 1, 2024

Comments 0

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Mes…

Feat. E. Efstathiou

16:05

Insights from 2024 ASCO® GU Annual Meeting

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini

27:04

Fengting Yan

Cancer Screening Molecular Tools

11:56

Ana Aparicio

Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment…

17:50

AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde

09:14

Robert Dreicer

AUA Advanced Prostate Cancer Guidelines: 2023 Update

29:25

Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

05:18

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "PSMAddition - A Phase 3 Trial to Compare …

Feat. S. Tagawa

34:26

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Prostate Cancer Highlights"

Feat. N. Reizine, K. Tawagi

03:05

Benjamin L. Maughan

Testosterone Suppression and Recovery in Patients With Advanced Pros…

08:05

Total Health

Prostate Cancer Updates From ASCO® 2023

Feat. T. Zhang

17:33

Insights from AUA 2024 Annual Meeting

AUA 2024 Insights: "Manipulating the Androgen Axis - New Agents…

Feat. D. Jarrard

11:39

Oncology Data Advisor

Recent Prostate Cancer Updates

Feat. U. Vaishampayan

21:17

Manish Kohli

Time to Castrate Resistance in mCSPC Using Standard of Care Intensif…

22:27

2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde

09:45

Northwestern Medicine Oncology and Hematology

Differences Between Urologists and Medical Oncologists in the Manage…

Feat. W. Catalona

19:07

Stanford Medicine

Stanford Medicine Advances in Imaging to Improve Prostate Cancer Dia…

Feat. G. Sonn

25:33

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Prostate Cancer Updates From ASCO GU 20…

Feat. J. Berchuck, A. Choudhury

12:39

ASCO GU 2023 Conference Coverage

Efficacy and Safety of Darolutamide in Combination With ADT and Doce…

Feat. C. Sternberg

10:13

Judd Moul

Login

Login

Join VuMedi

ASCO® GU 2024 Summary: "Tailoring Prostate Cancer Care - EMBARK Findings, QoL and Real-World Treatment Patterns for High-Risk Biochemically Recurrent Prostate Cancer & Real World Impact of Doublet Therapy in mCSPC"

Recommended